Quote
187.50
-5.81 (-3.01%)
We have scored 54 news catalysts on DVA (DVA) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in sector healthcare and earnings revision trend.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
173.34–187.72
Open
173.34
Prev close
193.31
Volume
1.8M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged DVA or its network in the window yet.
Show more DVA articles →Analysts publish price targets on DVA, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $194 to $270
as of 2026-09-04
The market is 17% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about DVA — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of DVA, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for DVA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the very bottom of the published analyst range, 17% below the median target and rejecting all eight bull cases, meaning the market expects DaVita's revenue and profit growth to fall well short of what the models project.
What the disagreement turns on
Can DaVita stabilize or grow its revenue per treatment and expand margins as one-time headwinds fade, or will declining commercial mix and stagnant volumes keep cash flow flat? The available data can measure treatment volumes via segment revenue history, but it cannot measure the crucial commercial payor pricing and mix shifts that drive profitability.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $182 on 2026-09-04 — 59 days ago.
